Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000011473 | SCV003445887 | uncertain significance | Fabry disease | 2023-04-05 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies have shown that this missense change affects GLA function (PMID: 17555407). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GLA protein function. ClinVar contains an entry for this variant (Variation ID: 10726). This missense change has been observed in individual(s) with clinical features of Fabry disease (PMID: 8012363, 17206462, 31956509; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 146 of the GLA protein (p.Pro146Ser). |
OMIM | RCV000011473 | SCV000031705 | pathogenic | Fabry disease | 2017-06-16 | no assertion criteria provided | literature only |